News articles about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.8554857948475 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- AMAG Pharmaceuticals (AMAG) Upgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
- AMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngine (americanbankingnews.com)
- AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 Million (americanbankingnews.com)
- Global Intravenous (IV) Iron Drugs Market 2018 – Sanofi US, Allergan, AMAG Pharmaceuticals, Dalichi Sankyo (businessservices24.com)
- Global Intravenous Iron Drugs Market 2018 – Daiichi Sankyo, AMAG Pharmaceuticals, Allergan, Galenica … (healthcaretrends24.com)
A number of analysts recently commented on AMAG shares. Jefferies Group cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price objective for the company from $21.00 to $20.00 in a research report on Monday, March 5th. B. Riley reiterated a “hold” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Tuesday, January 16th. Cantor Fitzgerald reiterated a “hold” rating and set a $17.00 price objective on shares of AMAG Pharmaceuticals in a research note on Wednesday, February 14th. ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 10th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $23.91.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.68. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The firm had revenue of $158.30 million during the quarter, compared to analyst estimates of $158.84 million. During the same quarter in the previous year, the business earned ($0.31) EPS. AMAG Pharmaceuticals’s revenue for the quarter was up 4.4% compared to the same quarter last year. analysts forecast that AMAG Pharmaceuticals will post -3.25 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.wkrb13.com/2018/04/02/amag-pharmaceuticals-amag-earning-somewhat-positive-press-coverage-analysis-finds.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.